CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Beraprost Sodium Modified Releasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00990314
NCT00990314Phase 2Completed
CompareCT.gov

An Open-label Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Lung Biotechnology PBC·interventional·Posted Oct 6, 2009·Updated Sep 16, 2019

In Brief

A Phase 2 clinical trial evaluating Beraprost Sodium Modified Release for Pulmonary Arterial Hypertension. Completed, enrolled 31 participants across 17 sites in 6 countries.

Detailed Summary

This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesBelgium, Czechia, Germany, Ireland, Romania, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 6, 2009
Enrollment StartNov 30, 2009
Primary CompletionNov 30, 2013
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.7 years ago

Interventions

Beraprost Sodium Modified Releasedrug